To sum up, IL-4 and IL-21 mainly suppressed the anti-IgM detrimental effects through the activation of JAK/STAT pathway, which might serve as the potential therapeutic target to treat autoimmune diseases associated with hyperreactive B cell pathology. The gene discussed is CD40LG; the disease is autoimmune disease.